Merck's Q1 2009 earnings call reflects several key factors likely to impact its stock in the short term. The company reported a decrease in revenue and cited challenges such as the loss of marketing exclusivity for key products, economic pressures affecting patients' spending on healthcare, and wholesaler destocking. However, there is a slightly positive outlook for the second half of the year with expected improvements in vaccine supply and continued growth prospects for products like JANUVIA and ISENTRESS. The market will likely focus on the near-term concerns and operational challenges, particularly with the pending merger with Schering-Plough and the delay in the telcagepant filing. Given these mixed signals, the stock may face mild pressure in the short term.

[-1]